NCT01401114View on ClinicalTrials.gov

Wellnara Post-marketing Surveillance in Japan

CompletedOBSERVATIONAL

Enrollment

411

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2014

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG

E2/LNG oral (Wellnara, BAY86-5029)

Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY